Conservative management of severe aortic stenosis led to higher all-cause death and heart failure hospitalization rates compared with initial aortic valve replacement.
Transcatheter aortic valve replacement (TAVR) resulted in low rates of all-cause mortality in high-risk patients with failed surgical bioprostheses.
TAVR with the Sapien 3 valve demonstrates high 1-year survival rate for high-risk and inoperable patients with aortic stenosis.
A patent foramen ovale (PFO) closure device significantly decreases recurrent cryptogenic ischemic stroke in patients with PFO who experienced a cryptogenic stroke.
Results from the BRAVO 3 study indicate major bleeding and 30-day net adverse clinical event rate were similar in patients receiving either bivalirudin or heparin during TAVR.
Results from the DRAGON study conclude that transradial intervention reduced the incidence of bleeding complications when compared with transfemoral intervention.
Polymer-free drug-coated stent demonstrated superiority vs bare-metal stent when used in conjunction with DAPT.
Results from the ISAR-DESIRE 4 clinical trial indicate that use of scoring balloon plus a paclitaxel-coated balloon was angiographically superior compared with drug-coated balloon alone.
IN.PACT SFA trial results reveal that drug-coated balloons demonstrate significantly higher primary patency compared with percutaneous transluminal angioplasty for patients with peripheral artery disease.
Second-generation sirolimus-eluting absorbable metal scaffold demonstrates favorable outcomes in de novo coronary artery lesions, as reported by the BIOSOLVE-II trial.
Please login or register first to view this content.
